Trials / Unknown
UnknownNCT03316469
Anti-Mullerian Hormone as Predictor of Ovarian Responce to Clomiphene Citrate in PCOS
Circulating Anti-mullerian Hormone as Predictor of Ovarian Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Ain Shams University · Academic / Other
- Sex
- Female
- Age
- 20 Years – 35 Years
- Healthy volunteers
- Not accepted
Summary
Polycystic ovary syndrome (PCOS) is found in 5% to 6% of women of reproductive age. It affects women's reproductive capability; thus patients have risks of infertility, miscarriage, and complicated pregnancy. A study revealed that the prevalence of oligoovulation or anovulation in patients with PCOS ranged from 65% to 80%. Anti-Mullerian Hormone (AMH) is an important regulator in the ovary that play a rule during development and function. It is suspected to affect clomiphene citrate (cc) resistance. In this study the investigator will assess the accuracy of AMH prediction of response to cc in women with PCOS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clomiphene Citrate | 100 mg daily will be provided to the subjects to be taken for 5 days starting from day 2 of their spontaneous periods |
| DIAGNOSTIC_TEST | Follicular growth | Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. |
Timeline
- Start date
- 2018-07-01
- Primary completion
- 2018-10-01
- Completion
- 2018-12-01
- First posted
- 2017-10-20
- Last updated
- 2018-06-27
Source: ClinicalTrials.gov record NCT03316469. Inclusion in this directory is not an endorsement.